Lichen Planopilaris Drugs Market

Lichen Planopilaris: Introduction

• Lichen planopilaris is a medical condition that causes scarring hair loss. It causes swelling and irritation on the skin, nails, and mucous membrane. It forms lacy white patches on mucous membrane, while on the skin it appears as reddish color, itchy, and flat bumps.
• Lichen planopilaris replaces the hair follicle on skin with scarring. It is most common in women than men. It is two to five times more prevalent in women than men and affects adults in their mid-40s. Common symptoms of lichen planopilaris include itchy scalp, pain, burning, and scalp tenderness. It also causes painful sores in the mouth and genial parts.
• Generally, symptoms of lichen planopilaris disappear naturally in a few months. However, medical treatment is required where it affects the mucous membrane. Common treatments include corticosteroids, oral anti-infective, immune response medicines, and antihistamines.

Key Drivers of Global Lichen Planopilaris Drugs Market

• The global lichen planopilaris drugs market is primarily driven by high prevalence of lichen planopilaris. Around 1% of the world’s population is affected by lichen planopilaris. People affected with hepatitis C are more susceptible to the condition. Hence, increase in the number of patients with hepatitis C is another key driver of the global lichen planopilaris drugs market.
• Launch of pipeline drugs during the forecast period is anticipated to contribute to the growth of the global lichen planopilaris drugs market

Corticosteroids Segment to be Highly Promising

• Based on drug type, the global planopilaris drugs market can be divided into antihistamines, corticosteroids, anti-infection drugs, immunomodulators, and others. Corticosteroids is expected to be the leading segment during the forecast period.
• Corticosteroids are used as first-line treatment for lichen planopilaris and inflammatory disorders. Topical corticosteroid preparations are most commonly used in the treatment of the condition. Corticosteroid drugs are utilized to relieve the symptoms of itching and rashes.
• Immunomodulators are used in the treatment of severe cases of lichen planopilaris. Commonly used immunomodulators are azathioprine, mycophenolate, cyclosporine, and methotrexate.
• Antihistamine drugs are used to reduce itching, rashes, and redness of skin

Topical Segment to Dominate Global Market

• In terms of route of administration, the global lichen planopilaris drugs market can be classified into oral, topical, and others. The topical segment is likely to dominate the global market during the forecast period.
• Topical is the most commonly used and preferred route of administration of the treatment of lichen planopilaris
• Oral is likely to be fastest growing segment during the forecast period

Retail Pharmacies to be Most Promising Segment

• Based on distribution channel, the global lichen planopilaris drugs market can be divided into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment accounted for significant market share in 2020. The segment is projected to witness strong growth during the forecast period.
• Increase in the number of lichen planopilaris drugs dispensed through retail pharmacies and rise in the number of retail pharmacies in developing countries render these pharmacies as a major distribution channel. Moreover, patients prefer retail pharmacies to purchase drugs, as these are easily accessible.

Asia Pacific to Dominate Global Lichen Planopilaris Drugs Market

• In terms of region, the global lichen planopilaris drugs market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to dominate the global market during the forecast period. However, the region is anticipated to lose market share by the end of 2027.
• High prevalence of lichen planopilaris in adults and high awareness and easy availability of medications are expected to drive the lichen planopilaris drugs market in North America during the forecast period
• The lichen planopilaris drugs market in Asia Pacific is projected to expand at a high CAGR during the forecast period. Growth of the market in Asia Pacific can be attributed to high prevalence of lichen planopilaris in densely populated countries such as India, China, and Hong Kong, rapidly improving health care infrastructure, and significantly high infection rate of hepatitis C.

Key Manufacturers Operating in Global Lichen Planopilaris Drugs Market

The global lichen planopilaris drugs market was highly fragmented in 2020. Key manufacturers operating in the global market are:

• Sanofi S.A.
• Teva Pharmaceutical Industries
• Mylan NV
• Aurobindo Pharma Limited
• Pfizer, Inc.
• Salix Pharmaceuticals, Inc.
• GlaxoSmithKline plc
• F. Hoffmann-La Roche AG
• Eli Lilly and Company
• Bausch Health Companies, Inc.
• Other prominent players

Global Lichen Planopilaris Drugs Market: Research Scope

Global Lichen Planopilaris Drugs Market, by Drug Type

• Corticosteroids
• Antihistamines
• Anti-infective Drugs
• Immunomodulators
• Others

Global Lichen Planopilaris Drugs Market, by Route of Administration

• Oral
• Topical
• Others

Global Lichen Planopilaris Drugs Market, by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Lichen Planopilaris Drugs Market, by Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa